137 related articles for article (PubMed ID: 16260851)
1. Adjuvant chemotherapy in 780 patients with early breast cancer: 10-year data from Saudi Arabia.
Ibrahim EM; Ezzat AA; Rahal MM; Raja MM; Ajarim DS
Med Oncol; 2005; 22(4):343-52. PubMed ID: 16260851
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
4. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease.
Rivera E; Holmes FA; Buzdar AU; Asmar L; Kau SW; Fraschini G; Walters R; Theriault RL; Hortobagyi GN
Breast J; 2002; 8(1):2-9. PubMed ID: 11856154
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
Mamounas EP; Bryant J; Lembersky B; Fehrenbacher L; Sedlacek SM; Fisher B; Wickerham DL; Yothers G; Soran A; Wolmark N
J Clin Oncol; 2005 Jun; 23(16):3686-96. PubMed ID: 15897552
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
7. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
8. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
Fisher B; Jeong JH; Anderson S; Wolmark N
J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
[TBL] [Abstract][Full Text] [Related]
9. Addition of adjuvant tamoxifen to cyclophosphamide, methotrexate and 5-fluorouracil for premenopausal women with oestrogen receptor-positive breast cancer.
Li HC; Wen XF; Hou YF; Shen KW; Wu J; Lu JS; Shen ZZ; Shao ZM
Asian J Surg; 2003 Jul; 26(3):163-8. PubMed ID: 12925292
[TBL] [Abstract][Full Text] [Related]
10. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
Kaufmann M; Jonat W; Abel U; Hilfrich J; Caffier H; Kreienberg R; Trams G; Brunnert K; Schermann J; Kleine W
J Clin Oncol; 1993 Mar; 11(3):454-60. PubMed ID: 8445420
[TBL] [Abstract][Full Text] [Related]
12. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
Adjuvant Breast Cancer Trials Collaborative Group
J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
14. 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.
Ferreira Filho AF; Crown J; Cardoso F; Nogaret JM; Duffy K; Dolci S; Rowan S; O'Higgins N; Batter V; Paesmans M; Piccart MJ; Di Leo A
Anticancer Res; 2002; 22(4):2471-6. PubMed ID: 12174946
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
Goldhirsch A; Gelber R
NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.
Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Rea S
Cancer; 2006 Feb; 106(3):514-23. PubMed ID: 16388519
[TBL] [Abstract][Full Text] [Related]
18. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
[TBL] [Abstract][Full Text] [Related]
19. One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
Ejlertsen B; Jensen MB; Elversang J; Rasmussen BB; Andersson M; Andersen J; Nielsen DL; Cold S; Mouridsen HT
Eur J Cancer; 2013 Sep; 49(14):2986-94. PubMed ID: 23756360
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients.
International Breast Cancer Study Group
J Clin Oncol; 1997 Apr; 15(4):1385-94. PubMed ID: 9193330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
